Journal September 25, 2026 6 min read

What does the research say about thyroid function?

A research-supply overview of thyroid function as studied in clinical and observational settings, covering levothyroxine adjuncts, autoimmune thyroid disease, pituitary-axis interactions, and metabolic correlates. For la

peptides-pro Editorial

Thyroid function refers to the hypothalamic-pituitary-thyroid axis and the synthesis, secretion, transport, and peripheral action of the thyroid hormones thyroxine (T4) and triiodothyronine (T3). In research settings, thyroid function is assessed through serum thyroid-stimulating hormone (TSH), free T4, free T3, and thyroid autoantibodies. The evidence block does not provide a sequence, formula, or molecular weight for thyroid hormones; those identifiers are therefore not stated here.

The work described in the evidence centres on the hypothalamic-pituitary-thyroid axis and its interactions with other endocrine pathways, including the growth hormone axis, the gonadotropin axis, and mineral-metabolism signalling through the soluble α-Klotho-fibroblast growth factor 23 (FGF23) axis.

Research Studies

Vitamin E and oxidative stress in levothyroxine-treated hypothyroidism

A registered clinical trial is evaluating whether vitamin E supplementation, given as an adjunct to levothyroxine therapy, reduces oxidative stress, improves antioxidant defence mechanisms, and favourably influences thyroid hormone status in patients with hypothyroidism [1]. The stated aim is to establish an evidence-based framework for integrating targeted antioxidant therapies into standard hypothyroid management strategies [1]. This is a study protocol; no outcome data are reported in the evidence block.

Enclomiphene and thyroid function in a cardiovascular case report

A case report described a 46-year-old man with prior mitral valve repair and chronic immune thrombocytopenia who developed newly detected atrial flutter after inadvertently increasing his enclomiphene dose from 25 mg daily to 50 mg daily [2]. Laboratory evaluation in that patient showed normal thyroid function, normal cardiac biomarkers, and normal electrolytes, alongside chronic thrombocytopenia with a platelet count of 36 × 10⁹/L [2]. The report notes that enclomiphene citrate is increasingly prescribed off-label for secondary male hypogonadism and that its cardiovascular safety profile remains poorly characterised [2].

Long-acting growth hormone analogs and other pituitary axes

A prospective observational monocentric study examined hormonal changes in children with isolated growth hormone deficiency (n = 33) starting the long-acting growth hormone analog somatrogon (n = 16) or switching from daily recombinant human growth hormone to the same weekly analog (n = 17) [3]. The study was designed to explore the impact of long-acting growth hormone formulations on pituitary axes beyond growth hormone, which the authors describe as unclear [3]. The evidence block does not report thyroid-specific results from this study.

Biomarkers and pharmacogenomics in major depressive disorder

A prospective, randomized, parallel-controlled trial plans to enrol 220 patients with major depressive disorder, allocated 1:1 to pharmacogenomics-guided therapy or conventional treatment, with a 12-week follow-up and a matched healthy control cohort for cross-sectional biomarker comparisons [4]. The background states that conventional antidepressants achieve only a 50% response rate and that objective biomarkers are lacking [4]. Thyroid function is not named as an endpoint in the evidence block.

Thyroid function panel in an obesity registry

A real-world registry study plans to enrol 10,000 patients with obesity across approximately 50 medical institutions in China [5]. Baseline assessments include a thyroid function panel of three items, alongside demographic data, physical examinations, multiple laboratory tests, and hepatic elasticity ultrasound [5]. Patients receive weight-loss therapy in routine clinical practice, with data on clinic visits, adverse events, and therapeutic regimen changes collected centrally [5].

Soluble α-Klotho and FGF23 in Hashimoto's thyroiditis

A prospective case-control study aims to compare serum soluble α-Klotho and FGF23 levels between adults with Hashimoto's thyroiditis and age- and sex-matched healthy controls, and to investigate their associations with thyroid function parameters and inflammatory markers [6]. The background describes Hashimoto's thyroiditis as the most common autoimmune thyroid disease and as a condition associated with chronic low-grade systemic inflammation beyond thyroid hormone dysfunction [6]. The soluble α-Klotho-FGF23 axis is described as central to mineral metabolism, inflammation, and aging-related pathways, with its involvement in Hashimoto's thyroiditis not adequately characterised [6].

Luteinizing hormone, hCG, and endocrine assessment

A study is evaluating the role of luteinizing hormone (LH) and human chorionic gonadotropin (hCG) in adult patients undergoing assessment for endocrine disorders [7]. The background notes that LH rises substantially after menopause and may rise in some men, and that small amounts of hCG can be detected in some postmenopausal women and older men [7]. Recent research suggests these hormones may influence bone health, body weight, kidney function, thyroid function, and adrenal gland function, though little is established [7].

Adipokines and metabolic parameters with levothyroxine replacement

A prospective observational study aims to evaluate changes in serum adipokine levels — including asprosin, adipolin, omentin-1, and visfatin — together with metabolic parameters in newly diagnosed primary hypothyroid patients before and after 8 weeks of levothyroxine replacement therapy [8]. The background states that primary hypothyroidism is associated with dyslipidemia, insulin resistance, adipose tissue dysfunction, and altered adipokine secretion, and that the extent to which biochemical recovery reflects metabolic improvement remains unclear [8].

Comparison of research models and populations

Study	Population or model	Thyroid-related focus
Vitamin E add-on trial [1]	Levothyroxine-treated hypothyroidism	Oxidative stress, antioxidant defence, thyroid hormone status
Enclomiphene case report [2]	46-year-old man with prior mitral valve repair and ITP	Thyroid function reported as normal
Long-acting growth hormone study [3]	Children with isolated growth hormone deficiency	Other pituitary axes, including thyroid
Depression pharmacogenomics trial [4]	Adults with major depressive disorder	Not a named endpoint
Obesity registry [5]	10,000 patients with obesity in China	Three-item thyroid function panel at baseline
Hashimoto's case-control study [6]	Adults with Hashimoto's thyroiditis vs. controls	Soluble α-Klotho, FGF23, thyroid function parameters
LH and hCG study [7]	Adults undergoing endocrine assessment	Possible influence on thyroid function
Adipokine study [8]	Newly diagnosed primary hypothyroidism	Adipokines and metabolic parameters before and after levothyroxine

Reference-only sources in the evidence block report on parathyroid function after lateral neck dissection in papillary thyroid carcinoma [9], persistent TSH elevation despite levothyroxine therapy revealing autoimmune adrenal insufficiency in an adolescent with autoimmune thyroiditis [10], goserelin versus leuprolide for ovarian function suppression in premenopausal breast cancer [11], and circulating omentin-1 and HMGB1 levels in Hashimoto thyroiditis [12]. These findings are noted here as context; they are not the focus of this page.

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or treatment recommendations. Anyone considering a compound for themselves should speak to a licensed clinician.